Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
30 Settembre 2024 - 3:00PM
Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”)
(NASDAQ: SONN), a clinical-stage company developing targeted
immunotherapeutic drugs, today announced the launch of its CEO
Corner platform featuring Pankaj Mohan, Founder and Chief Executive
Officer of Sonnet. The CEO Corner platform is intended to provide
additional in-depth perspective to press releases, events,
corporate updates and development pipeline progress.
“We believe that keeping our shareholders well
informed is crucial for the future success of Sonnet and we are
committed to executing on that belief,” commented Pankaj Mohan,
Founder and Chief Executive Officer of Sonnet. “The CEO Corner is a
new, additional way for us to connect directly with both current
and potential stockholders. As we move forward with our development
pipeline, the CEO Corner segments are intended to offer a broader
perspective on news releases, clinical studies, and other business
developments. We believe in the future of our FHAB platform and are
dedicated to growing value for all shareholders.”
The first segment of the CEO Corner is now
accessible on the Company’s website here. Segments on the CEO
Corner platform will be accessible on the Company’s website
(www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology
company with a proprietary platform for innovating biologic drugs
of single or bifunctional action. Known as FHAB (Fully Human
Albumin Binding), the technology utilizes a fully human single
chain antibody fragment (scFv) that binds to and "hitch-hikes" on
human serum albumin (HSA) for transport to target tissues. Sonnet's
FHAB was designed to specifically target tumor and lymphatic
tissue, with an improved therapeutic window for optimizing the
safety and efficacy of immune modulating biologic drugs. FHAB is
the foundation of a modular, plug-and-play construct for
potentiating a range of large molecule therapeutic classes,
including cytokines, peptides, antibodies, and vaccines.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the outcome of the Company’s
clinical trials, the Company's cash runway, the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential,” "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Relations Contact:JTC Team, LLCJenene
Thomas908.824.0775SONN@jtcir.com
Grafico Azioni Sonnet BioTherapeutics (NASDAQ:SONN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Sonnet BioTherapeutics (NASDAQ:SONN)
Storico
Da Dic 2023 a Dic 2024